Achievements: Past 12 Months

Our Own TAP Compounds

• Presentation of clinical data with our huN901-DM1 compound in the treatment of small-cell lung cancer.
• Expansion of the lead trial assessing huN901-DM1 for the treatment of small-cell lung cancer.
• Initiation of clinical testing with huN901-DM1 for the treatment of multiple myeloma.
• Advancement of our compound huC242-DM4 into clinical testing for the treatment of colorectal, pancreatic, and other CanAg-expressing cancers.

Collaboration TAP Compounds

• Presentation of clinical data by Millennium Pharmaceuticals, Inc. on their MLN2704 TAP compound for the treatment of prostate cancer.
• Advancement by the sanofi-aventis Group of their AVE9633 TAP compound into clinical testing for the treatment of acute myeloid leukemia.

Expansion of Collaborations

• Extension by the sanofi-aventis Group of the research collaboration between our two companies.
• Extension by Genentech of the agreement that grants them certain rights to test our TAP technology with their antibodies.
• Licensing by Genentech of the right to use our TAP technology with antibodies to two undisclosed targets in addition to their existing right to use it with antibodies to HER2.
• Licensing by Centocor, a Johnson & Johnson subsidiary, of the right to use our TAP technology with antibodies to an undisclosed target.
• Licensing by Biogen Idec of the right to use our TAP technology with antibodies to an undisclosed target.
• Substitution by Boehringer Ingelheim GmbH of a different target in their TAP technology license after development of the compound to their initial target was discontinued.